Vertex Pharmaceuticals Incorporated vs Vanguard Total International Stock Index Fund ETF — how do they compare? Vertex Pharmaceuticals Incorporated trades at $481.09 (market cap $121.95B), while Vanguard Total International Stock Index Fund ETF trades at $84.5. The key difference: Vanguard Total International Stock Index Fund ETF is trading nearer its 52-week high, Vertex Pharmaceuticals Incorporated nearer its low. Which is the better fit depends on your goals.
| VRTX | VXUS | |
|---|---|---|
Market Cap | $121.95B | — |
Sector | Health | Sector/Thematic |
52-Week High | $529.59 | $87.06 |
52-Week Low | $366.54 | $68.24 |
Enterprise Value | $116.69B | — |
Trailing returns across standard periods
Latest headlines on both assets
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →VXUS is a comprehensive, low-cost ETF that tracks the FTSE Global All Cap ex US Index, providing exposure to over 8,500 stocks in both developed and emerging markets outside the United States. It serves as a foundational building block for international diversification, allowing investors to own a market-cap-weighted slice of the entire non-U.S. investable equity universe in a single vehicle.
Read more on VXUS →